| Autor: |
Tomohiro Yonezawa, Cris Niño Bon B. Marasigan, Yuki Matsumiya, Shingo Maeda, Tomoki Motegi, Yasuyuki Momoi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Open Veterinary Journal, Vol 13, Iss 7, Pp 942-947 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2226-4485 |
| DOI: |
10.5455/OVJ.2023.v13.i7.14 |
| Popis: |
Background: The anti-epileptic effects of docosahexaenoic acid (DHA) in dogs and humans remain controversial. The dosage and efficacy of DHA were various in the previous reports. Aim: The effects of high-dose DHA supplementation as add-on therapy for idiopathic epilepsy in dogs were evaluated. Methods: An open-label clinical trial was designed in this pilot study. Six dogs (median age: 6 years) with idiopathic epilepsy were included. All the patients were diagnosed with idiopathic epilepsy using magnetic MRI and cerebrospinal fluid examination (median: 2.0 years before the trial). They had 5–45 seizures and/or auras (median: 9.0) in the month before starting DHA supplementation. DHA was adjunctively administered at doses of 69–166 mg/kg/day without changing other prescriptions. Results: Four of the six patients completed the 6-month observation period. All the patients showed a decrease in seizure frequency of 50% or more within 2–3 months after the start of the administration, and three patients decreased to a frequency of 0–1 per month after 5–6 months. No clear adverse events were observed in the general condition or blood test results in any patients. Conclusion: Although the sample size was small and the study was not a randomized controlled trial, the data suggest that add-on supplementation of DHA could be useful in reducing the frequency of seizures in canine idiopathic epilepsy. [Open Vet J 2023; 13(7.000): 942-947] |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
